Lowering TG with the apoC3 inhibitor, olezarsen, did not affect non-calcified plaque progression in patients with hypertriglyceridaemia at high risk of atherosclerosis in a one-year sub study of Essence-TIMI 73b presented at ACC.26 and published simultaneously in Circulation.1,2
